Epinephrine

Epinephrine activates alpha- and beta-adrenergic receptors. Its label describes vascular, cardiac, and bronchial effects that oppose the dangerous physiology of anaphylaxis. That is principally a downstream emergency mechanism, not evidence that epinephrine is a daily mast-cell stabilizer or a way to prevent an episode.

A 2025 practical MCAS approach places self-administered epinephrine outside its prophylactic sequence and discusses it for acute systemic episodes, particularly those meeting anaphylaxis criteria. The separate emergency catalog group preserves that distinction: H1 blockers and the numbered sequence address prevention or recurring symptoms, while this entry addresses a time-critical event.

The largest primary source cited here recorded 5,364 anaphylaxis reactions across emergency departments and compared prehospital treatment histories with later care. It was not randomized and did not identify an MCAS subgroup, so the associations cannot isolate a drug effect from event severity, treatment timing, or access. The current auto-injector label supplies the approval, device, and safety boundaries; it does not turn this page into personal emergency instructions.